---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-011863"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:32:18.275080+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics adopts amended bylaws raising quorum to 50% and enhancing shareholder proposal rules

## Summary
- Stockholder meeting quorum increased from one-third to 50% of shares entitled to vote.
- Meetings may be held virtually by remote communication; stockholder list examination requirement eliminated.
- Enhanced disclosure and representation requirements for stockholder proposals and director nominations.
- Clarified procedures for calling, postponing, rescheduling annual and special meetings.
- Added procedural requirements for universal proxy rules compliance under Rule 14a-19.

## SEC filing metadata
- accession: 0001493152-26-011863
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226011863/0001493152-26-011863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226011863/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-011863
- JSON: https://secwatch.observer/filing/0001493152-26-011863.json
- Plain text: https://secwatch.observer/filing/0001493152-26-011863.txt

## Source-grounded claims
- claim_id: a85ecbddb2d00248663535687cde545a16e0ed61
  claim: ABEONA THERAPEUTICS INC.: Adoption of Third Amended and Restated Bylaws effective March 16, 2026, making multiple changes including quorum increase to 50%, virtual meeting authorization, and enhanced stockholder proposal and director nomination procedures (effective 2026-03-16).
  evidence_excerpt: On March 16, 2026, the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) approved the adoption of the Third Amended and Restated Bylaws of the Company, effective as of March 16, 2026 (the “New Bylaws”), which amend and restate the Second Amended and Restated Bylaws of the Company, dated as of July 9, 2024 (the “Existing Bylaws”), in their entirety.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315226011863/0001493152-26-011863-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.